Clarion Blog

This is an exciting time for oncology drug development: the cancer pipeline is larger and more diverse than ever before. Many distinct technologies are in clinical use and in clinical trials today, including various small molecules, antibody-based therapies, cell therapies, DNA/RNA-based therapies, radiopharmaceuticals, and more. Although a wealth of technologies is likely necessary to address the complexities of cancer, it is also possible that not all approaches will succeed. Yet it remains unclear which technologies will bring transformative clinical benefit to patients—and are therefore worthy of intensive resource and time allocation—and which are not.

Dennis Chang, managing director at Clarion, joined a group of industry leaders to discuss the challenges and opportunities for advancing new modalities in oncology at the recent 4^th Annual Emerging Frontiers in Oncology Summit. Proceeds from the summit raised funds for Life Science Cares as part of the Timmerman Traverse campaign. Dennis’ talk titled “New Modalities at the Crossroads,” explores how we can potentially draw lessons from history to help us strike the right balance in which bets to place in oncology innovation.  Watch below:

Are you a company that is looking for guidance in the oncology space? Clarion is a life sciences strategy and organizational consultancy that works together with its clients to envision, craft, and enable growth through scientific and commercial innovation and leadership. Connect with us to learn how we can help you today.